Annuncio pubblicitario
Italia markets open in 3 hours 16 minutes
  • Dow Jones

    38.460,92
    -42,77 (-0,11%)
     
  • Nasdaq

    15.712,75
    +16,11 (+0,10%)
     
  • Nikkei 225

    37.818,11
    -641,97 (-1,67%)
     
  • EUR/USD

    1,0709
    +0,0008 (+0,07%)
     
  • Bitcoin EUR

    60.183,12
    -2.105,48 (-3,38%)
     
  • CMC Crypto 200

    1.389,38
    -34,72 (-2,44%)
     
  • HANG SENG

    17.321,64
    +120,37 (+0,70%)
     
  • S&P 500

    5.071,63
    +1,08 (+0,02%)
     

Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

Cara Therapeutics, Inc.
Cara Therapeutics, Inc.

STAMFORD, Conn., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 11:15 a.m. PST (2:15 p.m. EST) in San Francisco, CA.

A webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com